Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.

Literature DB >> 7799704

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.

A Howell¹, D DeFriend, J Robertson, R Blamey, P Walton.

Abstract

We treated 19 patients with advanced breast cancer resistant to tamoxifen with a new specific antioestrogen (ICI 182780) which, in animal studies, has no agonist activity. 13 (69%) patients responded (7 had partial responses and 6 showed no change) to monthly intramuscular injections of ICI 182780 after progression on tamoxifen, for a median duration of 18 months with minimum side effects. Preliminary evidence suggests that the agent is without effects on the liver or the hypothalamic-pituitary axis. ICI 182780 appears to be a promising new agent for treatment of advanced and early breast cancer.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1995 PMID： 7799704 DOI： 10.1016/s0140-6736(95)91156-1

Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321

Keyword Cloud
Cited

36 in total

1. IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis.

Authors: Yanxia Ning; Rebecca B Riggins; Jennifer E Mulla; Haniee Chung; Alan Zwart; Robert Clarke
Journal: Mol Cancer Ther Date: 2010-05 Impact factor: 6.261

Review 2. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.

Authors: Donald P McDonnell; Suzanne E Wardell
Journal: Curr Opin Pharmacol Date: 2010-12 Impact factor: 5.547

Review 3. Breast cancer therapies in development. A review of their pharmacology and clinical potential.

Authors: D de Valeriola; A Awada; J A Roy; A Di Leo; L Biganzoli; M Piccart
Journal: Drugs Date: 1997-09 Impact factor: 9.546

Review 4. The future of antihormone therapy: innovations based on an established principle.

Authors: K Parczyk; M R Schneider
Journal: J Cancer Res Clin Oncol Date: 1996 Impact factor: 4.553

5. Responsiveness to hormone, growth factor and drug treatment of a human breast cancer cell line: comparison between early and late cultures.

Authors: A de Cupis; P Pirani; L Fazzuoli; R E Favoni
Journal: In Vitro Cell Dev Biol Anim Date: 1998 Nov-Dec Impact factor: 2.416

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.

1. IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis.

Review 2. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.

Review 3. Breast cancer therapies in development. A review of their pharmacology and clinical potential.

Review 4. The future of antihormone therapy: innovations based on an established principle.

5. Responsiveness to hormone, growth factor and drug treatment of a human breast cancer cell line: comparison between early and late cultures.

6. Low-dose dietary genistein negates the therapeutic effect of tamoxifen in athymic nude mice.

7. ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1.

Review 8. Endocrine therapy of metastatic breast cancer.

9. Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells.

10. Designer interface peptide grafts target estrogen receptor alpha dimerization.